EGFR and non-small cell lung carcinoma: Although the evidence of osimertinib plus VEGF inhibitors in EGFR mutated NSCLC remains unknown, a phase 1/2 trial revealed that the combination of osimertinib and bevacizumab met the primary endpoint of progression‐free survival at 12 months; thus, a randomized phase 3 trial comparing osimertinib plus bevacizumab and osimertinib is planned.9